Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMTW79H)

Drug Name
GSK683699 Drug Info
Synonyms
4-Aminobutanoic acid; 4-aminobutyric acid; GABA; gamma-aminobutyric acid; 1956/12/2; Piperidic acid; Piperidinic acid; Aminalon; Mielogen; Gammalon; Gaballon; butanoic acid, 4-amino-; Mielomade; Gammalone; Gamarex; Gammasol; Gammar; Reanal; Immu-G; gamma-amino-n-butyric acid; gamma-Aminobutanoic acid; Butyric acid, 4-amino-; Gamastan; Gammagee; Gamulin; 4-aminobutyrate; omega-Aminobutyric acid; gamma-Aminobutyric acid; 3-Carboxypropylamine; gamma-Aminobuttersaeure; 4-amino-butanoic acid; gamma-Amino butyric acid; GAMMA-AMINO-BUTANOIC ACID
Indication
Disease Entry ICD 11 Status REF
Inflammatory bowel disease DD72 Phase 2 [1]
Cross-matching ID
PubChem CID
119
ChEBI ID
CHEBI:16865
CAS Number
CAS 56-12-2
TTD Drug ID
DMTW79H
VARIDT Drug ID
DR00831
INTEDE Drug ID
DR0087

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DTP
DME
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting GABA(A) receptor gamma-2 (GABRG2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Allopregnanolone DMNLHAC Depression 6A70-6A7Z approved [15]
THIOCOLCHICOSIDE DMEPWYA Muscle spasm MB47.3 Approved [4]
ZK-93423 DMFWMKZ Epileptic seizures 8A61-8A6Z Phase 3 [16]
ELTANOLONE DM38CIV Premenstrual syndrome GA34.40 Discontinued in Phase 3 [15]
U-78875 DM2WOPX Anxiety disorder 6B00-6B0Z Discontinued in Phase 1 [17]
CGS-9896 DM39PQI N. A. N. A. Terminated [18]
CGS-17867A DMMZJY3 Alcohol dependence 6C40.2 Terminated [19]
TBPS DMFC3XP Discovery agent N.A. Investigative [20]
AMENTOFLAVONE DMLRNV2 Discovery agent N.A. Investigative [21]
Ro-15-3505 DM4NW3U Discovery agent N.A. Investigative [22]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting GABA(A) receptor alpha-5 (GABRA5)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Flumazenil DMPCG2L Benzodiazepine overdose PC91 Approved [23]
Basmisanil DMQ8J0U Alzheimer disease 8A20 Phase 2 [24]
RG-7816 DMD16JK Autism spectrum disorder 6A02 Phase 1 [25]
TBPS DMFC3XP Discovery agent N.A. Investigative [23]
AMENTOFLAVONE DMLRNV2 Discovery agent N.A. Investigative [21]
Ro-15-3505 DM4NW3U Discovery agent N.A. Investigative [26]
isonipecotic acid DMO1ZHE Discovery agent N.A. Investigative [23]
[3H]Ro154513 DMMBWKL Discovery agent N.A. Investigative [27]
[3H]CGS8216 DMLP68J Inflammation 1A00-CA43.1 Investigative [23]
CI-218872 DM0RH3S Discovery agent N.A. Investigative [28]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting GABA transporter-3 (SLC6A11)
Drug Name Drug ID Indication ICD 11 Highest Status REF
NIPECOTIC ACID DMPV450 Discovery agent N.A. Investigative [3]
Beta-Alanine DMC64EI Discovery agent N.A. Investigative [29]
2,4-Diamino-butyric acid(GABA) DMAOGBP Discovery agent N.A. Investigative [30]
4-Hydroxy-piperidine-3-carboxylic acid DM9VQ0T Discovery agent N.A. Investigative [31]
Drug(s) Targeting Gamma-aminobutyric acid B receptor (GABBR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Gabapentin DM6T924 Complex partial seizure 8A68.0 Approved [32]
Gamma Hydroxybutyric Acid DMGBKVD Narcolepsy 7A20 Approved [33]
Baclofen DM0QV1J Multiple sclerosis 8A40 Approved [34]
Progabide DM671NG Depression 6A70-6A7Z Approved [35]
Arbaclofen placarbil DMO628K Fragile X syndrome LD55 Phase 3 [36]
[3H](R)-(-)-baclofen DMLRHM5 Multiple sclerosis 8A40 Phase 3 [37]
Arabaclofen DMZB9RI Fragile X syndrome LD55 Phase 3 [38]
SGS742 DM5XYFH Schizophrenia 6A20 Phase 2 [39]
SSTarbaclofen DMRGTZ2 Autism spectrum disorder 6A02 Phase 2 [40]
ASP8062 DMR1MIV Fibromyalgia MG30.01 Phase 2 [41]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting GABA(A) receptor alpha-2 (GABRA2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Flumazenil DMPCG2L Benzodiazepine overdose PC91 Approved [42]
PF-4480682 DMWYJHC Neuropathic pain 8E43.0 Discontinued in Phase 2 [43]
CGS-17867A DMMZJY3 Alcohol dependence 6C40.2 Terminated [19]
TBPS DMFC3XP Discovery agent N.A. Investigative [42]
AMENTOFLAVONE DMLRNV2 Discovery agent N.A. Investigative [21]
Ro-15-3505 DM4NW3U Discovery agent N.A. Investigative [26]
isonipecotic acid DMO1ZHE Discovery agent N.A. Investigative [42]
[3H]Ro154513 DMMBWKL Discovery agent N.A. Investigative [27]
[3H]CGS8216 DMLP68J Inflammation 1A00-CA43.1 Investigative [42]
CI-218872 DM0RH3S Discovery agent N.A. Investigative [28]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting GABA(A) receptor alpha-1 (GABRA1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ethanol DMDRQZU Chronic pain MG30 Approved [44]
Zolpidem DMWOSKJ Insomnia 7A00-7A0Z Approved [45]
Methoxyflurane DML0RAE Anaesthesia 9A78.6 Approved [44]
Nitrazepam DMEGIQ6 Epilepsy 8A60-8A68 Approved [44]
Allopregnanolone DMNLHAC Depression 6A70-6A7Z approved [15]
Clobazam - Lundbeck DMW1OQ0 Anxiety disorder 6B00-6B0Z Approved [44]
Hexobarbital DMQ314B Anaesthesia 9A78.6 Approved [44]
THIOCOLCHICOSIDE DMEPWYA Muscle spasm MB47.3 Approved [4]
Meprobamate DMHM93Y Anxiety Approved [44]
Zaleplon DMGFWSM Insomnia 7A00-7A0Z Approved [33]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting GABA transporter GAT-1 (SLC6A1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tiagabine DMKSQG0 Epilepsy 8A60-8A68 Approved [46]
Metadoxine DMM4QOJ Multiple myeloma 2A83 Approved [47]
CI-966 DM8T2KA Convulsion 8A68.Z Phase 1 [48]
NIPECOTIC ACID DMPV450 Discovery agent N.A. Investigative [3]
2,4-Diamino-butyric acid(GABA) DMAOGBP Discovery agent N.A. Investigative [30]
LU32-176B DM2YOVC Discovery agent N.A. Investigative [49]
(R)-nipecotic acid DMWGB40 Discovery agent N.A. Investigative [2]
4-Hydroxy-piperidine-3-carboxylic acid DM9VQ0T Discovery agent N.A. Investigative [31]
(R/S) EF-1500 DMYDG27 Discovery agent N.A. Investigative [46]
(R)-EF-1520 DM297MU Discovery agent N.A. Investigative [46]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting GABA(A) receptor alpha-3 (GABRA3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Flumazenil DMPCG2L Benzodiazepine overdose PC91 Approved [50]
Adipiplon DM821BS Sleep-wake disorder 7A00-7B2Z Phase 2 [51]
NS-2710 DMMUR6V Anxiety disorder 6B00-6B0Z Phase 2 [52]
AZD6280 DMFAZLU Anxiety disorder 6B00-6B0Z Discontinued in Phase 1 [53]
TBPS DMFC3XP Discovery agent N.A. Investigative [50]
AMENTOFLAVONE DMLRNV2 Discovery agent N.A. Investigative [21]
Ro-15-3505 DM4NW3U Discovery agent N.A. Investigative [26]
isonipecotic acid DMO1ZHE Discovery agent N.A. Investigative [50]
[3H]Ro154513 DMMBWKL Discovery agent N.A. Investigative [27]
[3H]CGS8216 DMLP68J Inflammation 1A00-CA43.1 Investigative [50]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Gamma-aminobutyric acid receptor (GAR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Phenobarbital DMXZOCG Cluster headache 8A81.0 Approved [44]
Allopregnanolone DMNLHAC Depression 6A70-6A7Z approved [54]
THIOCOLCHICOSIDE DMEPWYA Muscle spasm MB47.3 Approved [4]
Clonazepam DMTO13J Absence epilepsy Approved [55]
Piperazine DMTY9LU Ascariasis 1F62 Approved [56]
Alpidem DMN7Y9K Anxiety disorder 6B00-6B0Z Approved [57]
Moxidectin DMYGHX5 Onchocerciasis 1F6A Approved [58]
DP-VPA DMGOXPQ Bipolar disorder 6A60 Approved [59]
ANDROSTERONE DMITJAK N. A. N. A. Phase 3 [54]
ZK-93423 DMFWMKZ Epileptic seizures 8A61-8A6Z Phase 3 [16]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting GABA(A) receptor beta-2 (GABRB2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Allopregnanolone DMNLHAC Depression 6A70-6A7Z approved [15]
THIOCOLCHICOSIDE DMEPWYA Muscle spasm MB47.3 Approved [4]
Ethchlorvynol DM53IP1 Insomnia 7A00-7A0Z Approved [44]
ZK-93423 DMFWMKZ Epileptic seizures 8A61-8A6Z Phase 3 [16]
ELTANOLONE DM38CIV Premenstrual syndrome GA34.40 Discontinued in Phase 3 [15]
U-78875 DM2WOPX Anxiety disorder 6B00-6B0Z Discontinued in Phase 1 [60]
CGS-9896 DM39PQI N. A. N. A. Terminated [18]
TBPS DMFC3XP Discovery agent N.A. Investigative [61]
AMENTOFLAVONE DMLRNV2 Discovery agent N.A. Investigative [21]
Ro-15-3505 DM4NW3U Discovery agent N.A. Investigative [22]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Integrin alpha-4 (ITGA4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Vedolizmab DMV3YMX Crohn disease DD70 Approved [62]
Antegren DMNC64R Multiple sclerosis 8A40 Approved [63]
Natalizumab DMAK85L Crohn disease DD70 Approved [64]
PB006 DMVHGLA Crohn disease DD70 Phase 3 [65]
AMG-181 DMODJTX Crohn disease DD70 Phase 2 [66]
Senktide DMOH8LD Epilepsy 8A60-8A68 Phase 2 [67]
BIO-1211 DMKICA3 Asthma CA23 Phase 2 [68]
PTG-100 DMQNRGE Ulcerative colitis DD71 Phase 1 [66]
ELND-002 DMM9S51 Autoimmune diabetes 5A10 Phase 1 [69]
ELND-004 DMLQYVD Autoimmune diabetes 5A10 Phase 1 [69]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 2D6 (CYP2D6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [70]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [71]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [72]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [73]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [74]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [75]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [76]
Dopamine DMPGUCF Acromegaly 5A60.0 Approved [77]
Nicotine DMWX5CO Lung cancer 2C25.0 Approved [78]
Propranolol DM79NTF Angina pectoris BA40 Approved [79]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Sodium- and chloride-dependent GABA transporter 1 (SLC6A1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [80]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [81]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [82]
Bosentan DMIOGBU Pulmonary arterial hypertension BB01.0 Approved [83]
Tiagabine DMKSQG0 Epilepsy 8A60-8A68 Approved [84]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [81]
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [85]
SNDX-275 DMH7W9X Breast cancer 2C60-2C65 Phase 3 [86]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [87]
⏷ Show the Full List of 9 Drug(s)
Drug(s) Affected By Gamma-aminobutyric acid receptor subunit alpha-1 (GABRA1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Diazepam DM08E9O Alcohol withdrawal Approved [88]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [89]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [90]
Flunitrazepam DMGR5Z3 Insomnia 7A00-7A0Z Approved [91]
Arsenic DMTL2Y1 N. A. N. A. Approved [92]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [87]
bisphenol A DM2ZLD7 Discovery agent N.A. Investigative [93]
Trichostatin A DM9C8NX Solid tumour/cancer 2A00-2F9Z Investigative [94]
TBPS DMFC3XP Discovery agent N.A. Investigative [95]
Muscimol DMNTF2O Discovery agent N.A. Investigative [91]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Gamma-aminobutyric acid type B receptor subunit 1 (GABBR1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [93]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [96]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [97]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [98]
Arsenic DMTL2Y1 N. A. N. A. Approved [92]
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [85]
(+)-JQ1 DM1CZSJ Testicular cancer 2C80 Phase 1 [99]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [87]
bisphenol A DM2ZLD7 Discovery agent N.A. Investigative [93]
⏷ Show the Full List of 9 Drug(s)
Drug(s) Affected By Glutamate decarboxylase 1 (GAD1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methotrexate DM2TEOL Anterior urethra cancer Approved [100]
Quercetin DM3NC4M Obesity 5B81 Approved [101]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [96]
Acetic Acid, Glacial DM4SJ5Y infection in the ear canal AA0Y Approved [102]
Panobinostat DM58WKG Chronic graft versus host disease Approved [103]
Leflunomide DMR8ONJ Arthritis FA20 Approved [104]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [105]
Isoflurophate DMBSK7X Glaucoma/ocular hypertension 9C61 Approved [106]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [107]
Clozapine DMFC71L Schizophrenia 6A20 Approved [108]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Sodium- and chloride-dependent GABA transporter 3 (SLC6A11)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Quercetin DM3NC4M Obesity 5B81 Approved [101]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [109]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [98]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [110]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [87]
Milchsaure DM462BT Pruritus EC90 Investigative [111]
⏷ Show the Full List of 6 Drug(s)
Drug(s) Affected By Sodium- and chloride-dependent GABA transporter 2 (SLC6A13)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Testosterone DM7HUNW Hot flushes GA30 Approved [112]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [113]
Arsenic DMTL2Y1 N. A. N. A. Approved [114]
Triclosan DMZUR4N Malaria 1F40-1F45 Approved [115]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [87]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
GABA transporter GAT-1 (SLC6A1) TTPRKM0 SC6A1_HUMAN Inhibitor [2]
GABA transporter-3 (SLC6A11) TT8RXO5 S6A11_HUMAN Inhibitor [3]
GABA(A) receptor alpha-1 (GABRA1) TT1MPAY GBRA1_HUMAN Inhibitor [4]
GABA(A) receptor alpha-2 (GABRA2) TTBMV1G GBRA2_HUMAN Inhibitor [5]
GABA(A) receptor alpha-3 (GABRA3) TT37EDJ GBRA3_HUMAN Inhibitor [5]
GABA(A) receptor alpha-5 (GABRA5) TTNZPQ1 GBRA5_HUMAN Inhibitor [5]
GABA(A) receptor beta-2 (GABRB2) TTZA1NY GBRB2_HUMAN Inhibitor [4]
GABA(A) receptor gamma-2 (GABRG2) TT06RH5 GBRG2_HUMAN Inhibitor [4]
Gamma-aminobutyric acid B receptor (GABBR) TTDCVZW GABR1_HUMAN; GABR2_HUMAN Inhibitor [6]
Gamma-aminobutyric acid receptor (GAR) TTNJYV2 NOUNIPROTAC Inhibitor [4]
Integrin alpha-4 (ITGA4) TT4BT06 ITA4_HUMAN Binder [1]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Vesicular inhibitory amino acid transporter (SLC32A1) DTXQYLR VIAAT_HUMAN Substrate [7]
Sodium- and chloride-dependent GABA transporter 1 (SLC6A1) DT8Z563 SC6A1_HUMAN Substrate [8]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2D6 (CYP2D6) Main DME DECB0K3 CP2D6_HUMAN Substrate [9]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Gamma-aminobutyric acid receptor subunit alpha-1 (GABRA1) OTC2W96H GBRA1_HUMAN Drug Response [10]
Gamma-aminobutyric acid type B receptor subunit 1 (GABBR1) OTU5A52J GABR1_HUMAN Gene/Protein Processing [11]
Glutamate decarboxylase 1 (GAD1) OT52Z39J DCE1_HUMAN Biotransformations [12]
Sodium- and chloride-dependent GABA transporter 1 (SLC6A1) OTLCJJF3 SC6A1_HUMAN Regulation of Drug Effects [13]
Sodium- and chloride-dependent GABA transporter 2 (SLC6A13) OTAIXVTS S6A13_HUMAN Regulation of Drug Effects [14]
Sodium- and chloride-dependent GABA transporter 3 (SLC6A11) OT5F9PAE S6A11_HUMAN Regulation of Drug Effects [14]

References

1 Emerging drugs to treat Crohn's disease. Expert Opin Emerg Drugs. 2007 Mar;12(1):49-59.
2 Novel secoergoline derivatives inhibit both GABA and glutamate uptake in rat brain homogenates: synthesis, in vitro pharmacology, and modeling. J Med Chem. 2004 Nov 4;47(23):5620-9.
3 Epimeric cis-decahydroquinoline-5-carboxylic acids: effects on gamma-aminobutyric acid uptake and receptor binding in vitro. J Med Chem. 1981 Jul;24(7):788-94.
4 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
5 New anticonvulsants: Schiff bases of gamma-aminobutyric acid and gamma-aminobutyramide. J Med Chem. 1980 Jun;23(6):702-4.
6 3-Thienyl- and 3-furylaminobutyric acids. Synthesis and binding GABAB receptor studies. J Med Chem. 1991 Aug;34(8):2557-60.
7 Wakefulness Is Governed by GABA and Histamine Cotransmission. Neuron. 2015 Jul 1;87(1):164-78.
8 Mutations in the GABA Transporter SLC6A1 Cause Epilepsy with Myoclonic-Atonic Seizures. Am J Hum Genet. 2015 May 7;96(5):808-15.
9 Cytochrome P450 2D catalyze steroid 21-hydroxylation in the brain. Endocrinology. 2004 Feb;145(2):699-705.
10 Genetic essential tremor in gamma-aminobutyric acidA receptor alpha1 subunit knockout mice. J Clin Invest. 2005 Mar;115(3):774-9. doi: 10.1172/JCI23625.
11 The actions of ether, alcohol and alkane general anaesthetics on GABAA and glycine receptors and the effects of TM2 and TM3 mutations. Br J Pharmacol. 2000 Feb;129(4):731-43. doi: 10.1038/sj.bjp.0703087.
12 Homozygosity for a missense mutation in the 67 kDa isoform of glutamate decarboxylase in a family with autosomal recessive spastic cerebral palsy: parallels with Stiff-Person Syndrome and other movement disorders. BMC Neurol. 2004 Nov 30;4(1):20. doi: 10.1186/1471-2377-4-20.
13 Novel properties of a mouse gamma-aminobutyric acid transporter (GAT4). J Membr Biol. 2005 Jan;203(2):65-82. doi: 10.1007/s00232-004-0732-5.
14 Mechanisms of GABA release from human astrocytes. Glia. 2011 Nov;59(11):1600-11. doi: 10.1002/glia.21202. Epub 2011 Jul 11.
15 Neurosteroid analogues. 10. The effect of methyl group substitution at the C-6 and C-7 positions on the GABA modulatory and anesthetic actions of (... J Med Chem. 2005 Apr 21;48(8):3051-9.
16 Structural requirements for agonist actions at the benzodiazepine receptor: studies with analogues of 6-(benzyloxy)-4-(methoxymethyl)-beta-carbolin... J Med Chem. 1990 Mar;33(3):1062-9.
17 3-Phenyl-substituted imidazo[1,5-alpha]quinoxalin-4-ones and imidazo[1,5-alpha]quinoxaline ureas that have high affinity at the GABAA/benzodiazepin... J Med Chem. 1996 Sep 13;39(19):3820-36.
18 Synthesis, pharmacology, and structure-activity relationships of novel imidazolones and pyrrolones as modulators of GABAA receptors. J Med Chem. 2006 Mar 23;49(6):1855-66.
19 2,5-Dihydropyrazolo[4,3-c]pyridin-3-ones: functionally selective benzodiazepine binding site ligands on the GABAA receptor. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3441-4.
20 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 414).
21 Semisynthetic preparation of amentoflavone: A negative modulator at GABA(A) receptors. Bioorg Med Chem Lett. 2003 Jul 21;13(14):2281-4.
22 Synthesis and evaluation of imidazo[1,5-a][1,4]benzodiazepine esters with high affinities and selectivities at "diazepam-insensitive" benzodiazepin... J Med Chem. 1993 Apr 16;36(8):1001-6.
23 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 408).
24 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
25 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
26 The GABA(A) receptor as a target for photochromic molecules. Bioorg Med Chem. 2010 Nov 15;18(22):7731-8.
27 Synthesis and pharmacological properties of novel 8-substituted imidazobenzodiazepines: high-affinity, selective probes for alpha 5-containing GABA... J Med Chem. 1996 Apr 26;39(9):1928-34.
28 Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64.
29 Stable expression of a neuronal gamma-aminobutyric acid transporter, GAT-3, in mammalian cells demonstrates unique pharmacological properties and ion dependence. Mol Pharmacol. 1994 Sep;46(3):550-7.
30 Glycine antagonists. Synthesis, structure, and biological effects of some bicyclic 5-isoxazolol zwitterions. J Med Chem. 1986 Feb;29(2):224-9.
31 Hydroxy- and amino-substituted piperidinecarboxylic acids as gamma-aminobutyric acid agonists and uptake inhibitors. J Med Chem. 1982 Oct;25(10):1157-62.
32 Gabapentin increases a tonic inhibitory conductance in hippocampal pyramidal neurons. Anesthesiology. 2006 Aug;105(2):325-33.
33 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
34 Synthesis and pharmacology of the baclofen homologues 5-amino-4-(4-chlorophenyl)pentanoic acid and the R- and S-enantiomers of 5-amino-3-(4-chlorop... J Med Chem. 1999 Jun 3;42(11):2053-9.
35 Interactions between dopamine and GABA in the control of ambulatory activity and neophobia in the mouse. Pharmacol Biochem Behav. 1998 Jan;59(1):239-47.
36 Arbaclofen placarbil, a novel R-baclofen prodrug: improved absorption, distribution, metabolism, and elimination properties compared with R-baclofen.J Pharmacol Exp Ther.2009 Sep;330(3):911-21.
37 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 242).
38 Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome. Psychopharmacology (Berl). 2013 Jul;228(1):75-84.
39 SGS742: the first GABA(B) receptor antagonist in clinical trials. Biochem Pharmacol. 2004 Oct 15;68(8):1479-87.
40 Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen. Sci Transl Med. 2012 Sep 19;4(152):152ra128.
41 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
42 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 405).
43 WO patent application no. 2014,1515,17, Methods of improving microvascular integrity.
44 DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
45 Zolpidem, a selective GABA(A) receptor alpha1 subunit agonist, induces comparable Fos expression in oxytocinergic neurons of the hypothalamic paraventricular and accessory but not supraoptic nuclei in the rat.Brain Res Bull.2006 Dec 11;71(1-3):200-7.
46 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 929).
47 Company report (Alcobra pharma)
48 Tiagabine, SK&F 89976-A, CI-966, and NNC-711 are selective for the cloned GABA transporter GAT-1. Eur J Pharmacol. 1994 Oct 14;269(2):219-24.
49 First demonstration of a functional role for central nervous system betaine/{gamma}-aminobutyric acid transporter (mGAT2) based on synergistic anti... J Pharmacol Exp Ther. 2005 Feb;312(2):866-74.
50 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 406).
51 Discriminative stimulus properties of GABAA receptor positive allosteric modulators TPA023, ocinaplon and NG2-73 in rats trained to discriminate chlordiazepoxide or zolpidem. Eur J Pharmacol. 2011 Oct 1;668(1-2):190-3.
52 GABAA receptor subtype-selective modulators. I. alpha2/alpha3-selective agonists as non-sedating anxiolytics. Curr Top Med Chem. 2011;11(9):1176-202.
53 AZD6280, a novel partial -aminobutyric acid A receptor modulator, demonstrates a pharmacodynamically selective effect profile in healthy male volunteers.J Clin Psychopharmacol.2015 Feb;35(1):22-33.
54 Neurosteroid analogues. 11. Alternative ring system scaffolds: gamma-aminobutyric acid receptor modulation and anesthetic actions of benz[f]indenes. J Med Chem. 2006 Jul 27;49(15):4595-605.
55 Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17.
56 Cyclooctadepsipeptides--an anthelmintically active class of compounds exhibiting a novel mode of action. Int J Antimicrob Agents. 2003 Sep;22(3):318-31.
57 Synthesis and binding affinity of 2-phenylimidazo[1,2-alpha]pyridine derivatives for both central and peripheral benzodiazepine receptors. A new se... J Med Chem. 1997 Sep 12;40(19):3109-18.
58 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
59 DP-VPA D-Pharm. Curr Opin Investig Drugs. 2002 Jun;3(6):921-3.
60 High-affinity alpha-aminobutyric acid A/benzodiazepine ligands: synthesis and structure-activity relationship studies of a new series of tetracycli... J Med Chem. 1996 Nov 8;39(23):4654-66.
61 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 411).
62 Clinical pipeline report, company report or official report of Takeda (2009).
63 Very late antigen 4 (VLA4) antagonists as anti-inflammatory agents. Curr Opin Chem Biol. 1998 Aug;2(4):453-7.
64 Natalizumab in Multiple Sclerosis Treatment: From Biological Effects to Immune Monitoring. Front Immunol. 2020 Sep 24;11:549842.
65 Efficacy and Safety of Proposed Biosimilar Natalizumab (PB006) in Patients With Relapsing-Remitting Multiple Sclerosis: The Antelope Phase 3 Randomized Clinical Trial. JAMA Neurol. 2023 Mar 1;80(3):298-307.
66 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
67 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
68 A small-molecule, tight-binding inhibitor of the integrin alpha(4)beta(1) blocks antigen-induced airway responses and inflammation in experimental asthma in sheep. Am J Respir Crit Care Med. 2000 Aug;162(2 Pt 1):603-11.
69 Paxillin binding to the alpha 4 integrin subunit stimulates LFA-1 (integrin alpha L beta 2)-dependent T cell migration by augmenting the activation of focal adhesion kinase/proline-rich tyrosine kinase-2. J Immunol. 2003 Jun 15;170(12):5912-8.
70 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
71 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
72 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
73 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
74 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
75 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
76 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
77 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
78 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
79 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
80 Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
81 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
82 Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
83 Omics-based responses induced by bosentan in human hepatoma HepaRG cell cultures. Arch Toxicol. 2018 Jun;92(6):1939-1952.
84 GABA transporter deficiency causes tremor, ataxia, nervousness, and increased GABA-induced tonic conductance in cerebellum. J Neurosci. 2005 Mar 23;25(12):3234-45. doi: 10.1523/JNEUROSCI.3364-04.2005.
85 Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
86 Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
87 Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
88 GABAergic dysfunction in schizophrenia: new treatment strategies on the horizon. Psychopharmacology (Berl). 2005 Jul;180(2):191-205. doi: 10.1007/s00213-005-2212-8. Epub 2005 Apr 28.
89 Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
90 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
91 p-(4-Azipentyl)propofol: a potent photoreactive general anesthetic derivative of propofol. J Med Chem. 2011 Dec 8;54(23):8124-35. doi: 10.1021/jm200943f. Epub 2011 Nov 10.
92 Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
93 DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
94 From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects. Arch Toxicol. 2014 Jul;88(7):1451-68.
95 [3H]Ethynylbicycloorthobenzoate ([3H]EBOB) binding in recombinant GABAA receptors. Neurotoxicology. 2003 Dec;24(6):817-24. doi: 10.1016/S0161-813X(03)00051-2.
96 Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
97 Gene expression profile of multiple myeloma cell line treated by arsenic trioxide. J Huazhong Univ Sci Technolog Med Sci. 2007 Dec;27(6):646-9. doi: 10.1007/s11596-007-0606-z.
98 Stem cell transcriptome responses and corresponding biomarkers that indicate the transition from adaptive responses to cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
99 Bromodomain-containing protein 4 (BRD4) regulates RNA polymerase II serine 2 phosphorylation in human CD4+ T cells. J Biol Chem. 2012 Dec 14;287(51):43137-55.
100 Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
101 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
102 DNA methyltransferase inhibitors coordinately induce expression of the human reelin and glutamic acid decarboxylase 67 genes. Mol Pharmacol. 2007 Mar;71(3):644-53. doi: 10.1124/mol.106.030635. Epub 2006 Oct 25.
103 A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
104 Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
105 Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
106 Decarboxylases as hypothetical targets for actions of organophosphates: Molecular modeling for prediction of hidden and unexpected health threats. Food Chem Toxicol. 2022 Mar;161:112856. doi: 10.1016/j.fct.2022.112856. Epub 2022 Feb 11.
107 Neuronal and cardiac toxicity of pharmacological compounds identified through transcriptomic analysis of human pluripotent stem cell-derived embryoid bodies. Toxicol Appl Pharmacol. 2021 Dec 15;433:115792. doi: 10.1016/j.taap.2021.115792. Epub 2021 Nov 3.
108 Prefrontal dysfunction in schizophrenia involves mixed-lineage leukemia 1-regulated histone methylation at GABAergic gene promoters. J Neurosci. 2007 Oct 17;27(42):11254-62. doi: 10.1523/JNEUROSCI.3272-07.2007.
109 Differential gene expression in human hepatocyte cell lines exposed to the antiretroviral agent zidovudine. Arch Toxicol. 2014 Mar;88(3):609-23. doi: 10.1007/s00204-013-1169-3. Epub 2013 Nov 30.
110 Effect of ovarian steroids on gene expression profile in human uterine microvascular endothelial cells. Fertil Steril. 2009 Aug;92(2):709-21.
111 Transcriptional profiling of lactic acid treated reconstructed human epidermis reveals pathways underlying stinging and itch. Toxicol In Vitro. 2019 Jun;57:164-173.
112 The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
113 Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
114 Drinking-water arsenic exposure modulates gene expression in human lymphocytes from a U.S. population. Environ Health Perspect. 2008 Apr;116(4):524-31. doi: 10.1289/ehp.10861.
115 Transcriptome and DNA methylome dynamics during triclosan-induced cardiomyocyte differentiation toxicity. Stem Cells Int. 2018 Oct 29;2018:8608327.